Tempest Therapeutics

Working to improve the lives of patients through the development of novel and meaningful cancer therapeutics.

[Tempest Therapeutics @Tempest_Tx]

For the latest company updates, please visit our website, https://t.co/LmeaceXa4x or the $TPST LinkedIn page, https://t.co/xCpj1aZ8Pf.

[Tempest Therapeutics @Tempest_Tx]

Happy #NationalInternDay! $TPST interns play an important role in our mission to advance cancer research & innovation. Their passion and fresh perspectives inspire us daily. We’re proud to be cultivating the next generation of scientists who may join the fight against cancer.

[Tempest Therapeutics @Tempest_Tx]

Today we reported exciting new survival data from the ongoing global randomized Phase 1b/2 clinical study of amezalpat (TPST-1120) in randomized first-line HCC, including a stable 0.65 HR and a six-month improvement over the control arm.

Learn more here: https://t.co/bq4QMNy6x2

[Tempest Therapeutics @Tempest_Tx]

Tempest President and CEO, Stephen Brady, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 4:00 p.m. ET. Listen to the live or archived presentation here: https://t.co/yBQ4QEYc3S

[Tempest Therapeutics @Tempest_Tx]

$TPST President and CEO, Stephen Brady, and CMO and Head of R&D, Sam Whiting, MD, PhD, will discuss the latest company updates in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit on Wed, May 29, 2024 at 2:00 p.m. ET.
Listen here: https://t.co/yBQ4QEYc3S

[Tempest Therapeutics @Tempest_Tx]

Happy Administrative Professionals' Day! Today, we celebrate the incredible talent and dedication of our G&A teams in pursuit of bringing lifesaving drugs to cancer patients. Your contributions are invaluable.

Thank you for all you do! #AdminProfessionalsDay

[Tempest Therapeutics @Tempest_Tx]

This week we reported preclinical data at #AACR2024 demonstrating that TPST-1120 reduced tumor growth in kidney cancer as a monotherapy, as well as increased anti-cancer activity in combination with frontline chemotherapy and immunotherapy. Read more here: https://t.co/A53jELlnHn

[Tempest Therapeutics @Tempest_Tx]

Today we announced that @CRC_AACR published positive data from the earlier phase 1 trial of TPST-1120 in advanced solid tumors. Data demonstrated clinical activity of TPST-1120 as a monotherapy and in combination with nivolumab.

Read more here: https://t.co/rdeXxS5V2D

[Tempest Therapeutics @Tempest_Tx]

Yesterday we presented new preclinical data at the SITC 2024 Spring Scientific meeting showing potent anti-tumor activity in several cancer models treated with TPST-1120 alone or with immune checkpoint inhibitors. Learn more here: https://t.co/vDHvpydsDV

[Tempest Therapeutics @Tempest_Tx]

$TPST team members will join other industry experts at the SITC Spring Scientific Meeting taking place March 10-12, 2024 in Miami, FL. Be sure to stop by our TPST-1120 poster, #70 and say hello if you’re in attendance.

[Tempest Therapeutics @Tempest_Tx]

We are pleased to share that $TPST collaborators at @BIDMChealth will present a poster with preclinical data supporting the advancement of TPST-1120 as a potential treatment for renal cell carcinoma (RCC) at #AACR2024. Learn more here: https://t.co/eNNoIGNyIP

[Tempest Therapeutics @Tempest_Tx]

Tempest President and CEO, Stephen Brady, will present a company overview at the 44th Annual @TDCowen Health Care Conference on Monday, March 4, 2024 at 9:10 a.m. ET.

Listen to the live or archived presentation here: https://t.co/yBQ4QEYc3S

[Tempest Therapeutics @Tempest_Tx]

Empowering women and girls in science isn't just about equality; it's about unlocking untapped potential, driving innovation, and shaping a brighter future for all.
Let’s celebrate the remarkable achievements of women & girls in STEM! #WomenInScience #GirlsInScience

[Tempest Therapeutics @Tempest_Tx]

$TPST President & CEO, Steve Brady, and CMO & Head of R&D, Sam Whiting, will discuss recently reported exciting positive TPST-1120 data and company updates at the 35thAnnual @Piper_Sandler Healthcare Conference on Tues, Nov 28th at 3:00 p.m. ET.

https://t.co/yBQ4QEXEek

[Tempest Therapeutics @Tempest_Tx]

Check out CEO Stephen Brady discuss the recent report of exciting positive randomized data in first-line HCC with TPST-1120 as a potential treatment for liver cancer and the future of $TPST on @biztalkradio with hosts @sullyspeaks and Mike Costa.

https://t.co/rPiWkrKtkd

[Tempest Therapeutics @Tempest_Tx]

We are pleased to share exciting new and updated positive data from the ongoing global randomized Phase 1b/2 clinical study of TPST-1120 in first-line HCC.

Data reported demonstrate superiority of the TPST-1120 arm across multiple study endpoints.

https://t.co/hBmCckhd7P

[Tempest Therapeutics @Tempest_Tx]

We’re pleased to share that $TPST chief medical officer Sam Whiting M.D., Ph.D., has expanded his role to include head of R&D.

In this role, Sam will continue to oversee clinical development as well as advance our preclinical programs.

Read more here: https://t.co/RFlODxKjF9

[Tempest Therapeutics @Tempest_Tx]

$TPST CMO Sam Whiting, M.D., Ph.D., will present a company overview at the @HCWCO 25th Annual Global Investment Conference. Listen to the presentation on-demand starting Monday, September 11, 2023 at 7:00 p.m. ET here: https://t.co/wEfAj0ltqk

[Tempest Therapeutics @Tempest_Tx]

Don’t miss CEO Steve Brady & @biztalkradio hosts @sullyspeaks and Mike Costa dive into the $TPST oncology portfolio including a discussion on early positive data from our randomized Phase 1b/2 combination study of TPST-1120 in first line HCC. Watch here: https://t.co/3BqyCeXlD0

[Tempest Therapeutics @Tempest_Tx]

Watch $TPST CEO Steve Brady on @biztalkradio with host @sullyspeaks discuss our diverse portfolio of novel oncology programs with the potential to treat a wide range of cancer types and what’s on the horizon for the company, here: https://t.co/wUWW5030GG